A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer
ObjectivePD-1/PD-L1 inhibitors are novel immunotherapeutic agents that have been approved for first-line treatment in advanced non-small cell lung cancer (NSCLC). This study aims to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors, which have completed phase 3 clinical trials, as a first-li...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2025-01-01
|
| Серія: | Frontiers in Pharmacology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1516735/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|